权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Daily stress processes and sympathetic reactivity in depression

抑郁症的日常压力过程和交感神经反应

基本信息

批准号：
10376793
负责人：
Jody Greaney
金额：
$ 19.53万
依托单位：
UNIVERSITY OF TEXAS ARLINGTON
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-04-01 至 2023-08-15
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10376793
关键词：
Acute Adult Affect Affective Behavior Blood Pressure Cessation of life Chronic Chronic stress Clinical Cognitive Development Dimensions Disease Emotional Emotions Ensure Etiology Event Exposure to Functional disorder Future Goals Health Heterogeneity Individual Intervention Laboratories Life Link Major Depressive Disorder Measurement Measures Mediator of activation protein Mental Depression Mental Health Minor Nerve Neurocognitive Outcome Parents Pathogenesis Pathogenicity Pathologic Physiological Physiology Play Poverty Predisposition Prevalence Prevention strategy Process Psychological Stress Psychosocial Stress Public Health Regulation Research Design Research Domain Criteria Role Severities Stress Sympathetic Nervous System Symptoms System Testing Therapeutic Therapeutic Intervention acute stress arterial stiffness base biological adaptation to stress biosignature burden of illness cerebral microvasculature cerebrovascular clinically relevant depressive symptoms diaries disability disorder risk insight negative affect neurovascular novel physical conditioning pressure preventive intervention prospective psychologic psychological stressor psychosocial stressors resilience response stress reactivity stressor targeted treatment treatment strategy young adult

项目摘要

PROJECT SUMMARY/ABSTRACT Major depressive disorder (MDD) is a staggering public health challenge, manifesting in ~10% of adults in the US and contributing substantially to the global burden of disease and disability. Considering the increasing prevalence of MDD, particularly in young adulthood, it is critical to understand the pathophysiological underpinnings of MDD across a broad spectrum of function in order to identify individually-tailored preventive and therapeutic interventions. Given the intimate reciprocal link between stress and MDD, a better understanding of the mechanisms underlying stress system dysfunction in MDD may provide clinically relevant insight into such treatment strategies. The central scientific premise of this proposal is that MDD serves as a vulnerability factor that sensitizes and amplifies the functional link between daily psychosocial stress processes and acute sympathetic stress reactivity. Accordingly, determining the sympathetic neurovascular consequences of naturalistic daily psychosocial stress exposure may provide insight into the pathogenesis of MDD in stress- susceptible individuals, representing a novel biosignature of MDD. Aim 1 will examine the effect of daily psychosocial stress exposure on acute sympathetic stress reactivity in MDD. Aim 2 will determine the relation between negative affective reactivity to daily psychosocial stress exposure (i.e., increase in negative affect in response to stress) and acute sympathetic stress reactivity in MDD. Our integrative multi-pronged technical approach combines the comprehensive assessment of cumulative exposure and emotional responsiveness to naturalistic everyday psychosocial stressors (ambulatory daily diary-based approach) with the direct measurement of sympathetic reactivity (microneurography) during acute laboratory-applied emotional and cognitive stressors. Consistent with the Research Domain Criteria (RDoC) framework and to ensure the assessment of stress reactivity across a full spectrum of function, we will test adults with MDD having a broad range of symptom severity, as well as healthy non-depressed adults. Identification of the functional link between daily stressors and sympathetic reactivity in MDD is the necessary first step for future studies designed to examine novel targeted treatment and preventative strategies to induce emotional, cognitive, and physiological resilience to stress, thereby mitigating current—and reducing susceptibility toward future—psychiatric, cerebrovascular, and neurocognitive diseases.

项目总结/文摘